Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma Article Swipe

PDF

Related Concepts

Medicine Pembrolizumab Pancreatic ductal adenocarcinoma Pancreatic cancer Immunotherapy Adenocarcinoma Radiation therapy Oncology Complete response Immune system Internal medicine Cancer Cancer research Chemotherapy Immunology

Patrick M. McCarthy , Matthew Rendo , Matthew D Uy , Alexandra M. Adams , Anne E. O’Shea , Daniel W. Nelson , Joshua Fenderson , Katherine Cebe , Robert Krell , Guy T. Clifton , George E. Peoples , Timothy J. Vreeland ·

YOU? · · 2021 · Open Access · · DOI: https://doi.org/10.2147/ott.s311661 · OA: W3171147818

Pancreatic ductal adenocarcinoma (PDAC) remains deadly despite advances in systemic therapies and surgical techniques. While there is increasing utilization of immune therapies across diverse cancer types, PDAC remains generally resistant to these treatments. We report a case of locally advanced PDAC treated with preoperative radiation and anti-PD-1 immunotherapy guided by preoperative PD-L1 tumor analysis. After 4 months of preoperative therapy, the patient was submitted to resection, demonstrating a near-complete pathologic response on final tumor analysis. We will discuss the relevant literature and current state of immunotherapeutics for PDAC.